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Introduction: The ROS1 gene rearrangement has become
an important biomarker in NSCLC. The College of American
Pathologists/International Association for the Study of Lung
Cancer/Association for Molecular Pathology testing guide-
lines support the use of ROS1 immunohistochemistry (IHC)
as a screening test, followed by confirmation with fluores-
cence in situ hybridization (FISH) or a molecular test in all
positive results. We have evaluated a novel anti-ROS1 IHC
antibody (SP384) in a large multicenter series to obtain
real-world data.
Methods: A total of 43 ROS1 FISH–positive and 193 ROS1
FISH–negative NSCLC samples were studied. All specimens
were screened by using two antibodies (clone D4D6 from
Cell Signaling Technology and clone SP384 from Ventana
Medical Systems), and the different interpretation criteria
were compared with break-apart FISH (Vysis). FISH-
positive samples were also analyzed with next-generation
sequencing (Oncomine Dx Target Test Panel, Thermo
Fisher Scientific).
Results: An H-score of 150 or higher or the presence of at
least 70% of tumor cells with an intensity of staining of 2þ
or higher by the SP384 clone was the optimal cutoff value
(both with 93% sensitivity and 100% specificity). The D4D6
clone showed similar results, with an H-score of at least 100(91% sensitivity and 100% specificity). ROS1 expression in
normal lung was more frequent with use of the SP384 clone
(p < 0.0001). The ezrin gene (EZR)-ROS1 variant was
associated with membranous staining and an isolated green
signal FISH pattern (p ¼ 0.001 and p ¼ 0.017, respectively).
Conclusions: The new SP384 ROS1 IHC clone showed
excellent sensitivity without compromising specificity, so it
is another excellent analytical option for the proposed
testing algorithm.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: ROS1; Immunohistochemistry; FISH; Next-
generation sequencing; Lung carcinoma
Introduction
The ROS1 gene rearrangement has now become an
important predictive biomarker for targeted tyrosine
kinase inhibitors in NSCLC. In March 2016, crizotinib
was approved by the U.S. Food and Drug Administration
(FDA) for the treatment of patients with advanced ROS1-
rearranged NSCLCs without the requirement of use of an
2122 Conde et al Journal of Thoracic Oncology Vol. 14 No. 12FDA-approved companion diagnostic test.1 Soon after-
ward, the drug was approved by the European Medicines
Agency, with the statement that “an accurate and vali-
dated ROS1 assay is necessary for the selection of pa-
tients.”2 On the basis of the excellent results of the
crizotinib clinical trials and the development of other
ROS1 inhibitors with consistent efficacy results in
this patient population, the importance of accurately
identifying ROS1-positive lung cancer has never been
greater.3-8
Regarding the detection of ROS1 rearrangements,
the recently updated College of American Patholo-
gists/International Association for the Study of Lung
Cancer/Association for Molecular Pathology (CAP/
IASLC/AMP) molecular testing guidelines for the se-
lection of patients with lung cancer support the use
of ROS1 immunohistochemistry (IHC) as a screening
test, followed by fluorescence in situ hybridization
(FISH) (traditionally considered to be the criterion
standard method)9 or a molecular test (i.e., reverse-
transcriptase polymerase chain reaction or next-
generation sequencing [NGS]) in all cases with posi-
tive IHC results.10 To date, only one anti-ROS1 IHC
clone has been commercially available, and there is
no universally accepted criterion for the interpreta-
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Figure 1. Flowchart of patients in the ROSING study. *ROS1 flu
defined as those with more than 25 (50%) break-apart (BA) sign
negative samples were defined as those with fewer than five (10
were defined as those with more than 25 (50%) break-apart (B
immunohistochemistry; NGS, next-generation sequencing.This situation prompted us to evaluate a novel anti-
ROS1 IHC antibody in a large multicenter series to
obtain real-world data for the proposed ROS1 testing
algorithm.Material and Methods
Study Design and Tumor Samples
The flow diagram is depicted in Figure 1. A total of 55
ROS1-positive samples from patients with NSCLCs that
had been initially tested as part of routine clinical care in
23 different institutions were used for this study (also
known as ROSING [ROS IHC and NGS]). To confirm the
ROS1-positive status, FISH analysis (the criterion stan-
dard method) was performed at the referral institution
(i.e., University Hospital HM Sanchinarro). Only cases
with enough tissue available (i.e., 50 tumor cells, as per
the FISH test requirements) and ROS1 FISH–confirmed
positivity were included. In addition, 193 consecutive
ROS1 FISH–negative samples from NSCLCs tested at 14
of the participating institutions as part of routine clinical
care were included as negative controls. The material
available for all tumors was formalin-fixed and paraffin-
embedded (FFPE). The specifics of formalin fixation
were unknown. All cases were reviewed by two pa-
thologists (E. C. and F. L-R.). In addition to beingROS1-negave tumor samples
n = 193
ROS1-negave samples by FISH*
n = 193








Excluded (n = 12)
- Less than 50 tumor cells (n = 4)
- FISH not evaluable (n = 8)
Excluded (n = 9)
- Insufficient sequencing coverage
orescence in situ hybridization (FISH)–positive samples were
als or isolated green signals (IGS) in tumor cells. ROS1 FISH–
%) BA signals or IGS in tumor cells. ROS1 FISH–positive samples
A) signals or isolated green signals (IGS) in tumor cells. IHC,
December 2019 ROS1 Immunohistochemistry with Clone SP384 2123investigated by FISH, all specimens (negative and posi-
tive) were independently screened for ROS1 expression
by using two IHC antibodies. ROS1 FISH–positive cases
were also tested by NGS. Clinical data from patients with
ROS1 FISH–positive tumors were collected. The institu-
tional ethics committee at Grupo HM Hospitals reviewed
and approved this study. Each referring institution
regulated the need for additional specific consent, as
ROS1 testing is part of routine clinical care. Clinical data
were retrieved from the patient clinical records.FISH for ROS1 Rearrangements
FISH was repeated centrally on unstained 4-mm-thick
FFPE tumor tissue sections from all positive and nega-
tive cases. The Vysis 6q22 ROS1 Break Apart FISH Probe
Kit (Abbott Molecular, Des Plaines, IL) was used
following the manufacturer’s instructions as previously
described.12 The ROS1 FISH assay was independently
captured and scored with the automated BioView Duet
scanning system (BioView, Rehovot, Israel) by an expe-
rienced lung pathologist (E. C.) and molecular biologist
(S. H.). The interpretation criteria strictly followed highly
recommended criteria.11 A minimum of 50 tumor nuclei
were counted. ROS1 FISH–positive cases were defined as
those with more than 25 break-apart (BA) signals (50%)
(separated by at least one signal diameter) or an isolated
green signal (IGS) in tumor cells. ROS1 FISH–negative
samples were defined as those with fewer than five
(10%) BA signals or IGS in tumor cells. ROS1 FISH cases
were considered borderline if five to 25 (10%–50%)
cells were positive. In the case of borderline results, a
second reader evaluated the slide, added cell count
readings from the already automatically captured im-
ages, and calculated the percentage out of 100 cells. If
the percentage of positive cells was lower than 15%, the
sample was considered negative. If the percentage of
positive cells was higher than or equal to 15%, the
sample was considered positive.11IHC for ROS1 Expression
Automated IHC for ROS1 expression was performed
for all cases on a BenchMark ULTRA staining instrument
(Ventana Medical Systems, Tucson, AZ). FFPE tumor
tissues were sectioned at a thickness of 4 mm and
stained with two different anti-ROS1 clones: SP384
(Ventana Medical Systems) and D4D6 (Cell Signaling
Technology, Danvers, MA). Briefly, the Ventana ROS1
(SP384) ready-to-use rabbit monoclonal primary anti-
body was applied with the OptiView DAB IHC Detection
Kit and OptiView Amplification Kit, following the man-
ufacturer’s instructions. The D4D6 clone was used at a
1:50 dilution. Detection was performed with the same
OptiView detection-amplification kit. FISH-validatedROS1-positive external controls were included in all
the slides.
The slides were reviewed by two pathologists (E. C.
and F. L-R.) who were blinded to the FISH results. When
a discrepancy was observed, the final result was ob-
tained by consensus. Staining intensity was defined as
follows: strong cytoplasmic staining (3þ), which was
clearly visible with use of a 2 or 4 objective; mod-
erate staining (2þ), which required use of a 10 or 20
objective; weak staining (1þ), which involved use of a
40 objective; and negative staining (0), which was
defined as absence of expression.12 The percentages of
tumor cells with each staining intensity were also eval-
uated. Membrane staining was recorded when observed.
ROS1 IHC staining results with both clones were finally
interpreted by using four previously described criteria:
(1) an H-score with a threshold for ROS1 positivity
defined as at least 100,11,13 (2) an H-score cutoff of at
least 150,11,14 (3) an intensity criterion with the cutoff of
positivity defined as 2þ or higher in any tumor
cells,11,15,16 and (4) a positive status based on an in-
tensity of 2þ or higher in at least 30% of the total tumor
cells.17 Intratumoral staining heterogeneity was also
evaluated. It was defined as the presence of areas of
staining with an intensity of 0 or 1þ in positive cases.16
The positivity of normal lung tissue was recorded when
it was present on the sections.NGS for ROS1 Rearrangements
For each FFPE tumor sample, freshly cut 5-mm-thick
sections were collected for nucleic acid extraction: five
sections for surgical specimens and 12 sections for small
biopsy specimens. The first and last sections were
stained with hematoxylin and eosin and reviewed by two
pathologists (E. C. and F. L.-R.) to assess the percentage
of tumor cells. RNA extraction was performed with the
RecoverAll Total Nucleic Acid Isolation Kit (Thermo
Fisher Scientific, Vilnius, Lithuania) following the man-
ufacturer’s instructions. The RNA was then purified and
concentrated by using the GeneJET RNA cleanup and
concentration micro kit (Thermo Fisher Scientific).
The Oncomine Dx Target Test panel (Thermo Fisher
Scientific) was the selected approach because it requires
very little input RNA and it was the first FDA-approved
NGS test. The protocol for the NGS analysis followed
the manufacturer0s instructions, and a minimum of 5000
mapped fusion panel reads was required for ROS1 fusion
analysis. Consent was granted only for the RNA part of
the procedure.Statistical Analysis
On the basis of all the valid data obtained, we per-
formed a descriptive analysis of all the variables of
Table 1. Performance of ROS1 IHC Using the Previously Published Criteria to Predict ROS1 Rearrangements by FISH
ROS1 IHC IHC Result
ROS1 FISH










Criterion 1: H-score 100 IHC-positive 40 1 41 (17.4) 93 (81–98) 99 (97–100) 180 (25.4–1270) 0.1 (0–0.2)
IHC-negative 3 192 195 (82.6)
Criterion 2: H-score 150 IHC-positive 40 0 40 (16.9) 93 (81–98) 100 (98–100) 0.1 (0–0.2)
IHC-negative 3 193 196 (83.1)
Criterion 3: 2þ staining IHC-positive 40 31 71 (30.1) 93 (81–98) 84 (78–89) 5.8 (4.1–8) 0.1 (0–0.2)
IHC-negative 3 162 165 (69.9)
Criterion 4: 2þ staining
in 30% of tumor cells
IHC-positive 40 1 41 (17.4) 93 (81–98) 99 (97–100) 180 (25.4–1270) 0.1 (0–0.2)
IHC-negative 3 192 195 (82.6)
Clone D4D6
Criterion 1: H-score 100 IHC-positive 39 0 39 (16.5) 91 (78–97) 100 (98–100) 0.1 (0–0.2)
IHC-negative 4 193 197 (83.5)
Criterion 2: H-score 150 IHC-positive 37 0 37 (15.7) 86 (72–95) 100 (98–100) 0.1 (0.1–0.3)
IHC-negative 6 193 199 (84.3)
Criterion 3: 2þ staining IHC-positive 39 14 53 (22.5) 91 (78–97) 93 (88–96) 12.5 (7.5–20.9) 0.1 (0–0.2)
IHC-negative 4 179 183 (77.5)
Criterion 4: 2þ staining in 30% of
tumor cells
IHC-positive 37 0 37 (15.7) 86 (72–95) 100 (98–100) 0.1 (0.1–0.3)
IHC-negative 6 193 199 (84.3)
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SP384 ROS1 IHC 
≥ 2+ staining in ≥ 70% of total tumor cells
D4D6 ROS1 IHC 
H-score ≥ 100
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D4D6 ROS1 IHC 
≥ 2+ staining in ≥ 30% of total tumor cells
Area under ROC curve = 0.9496
Figure 2. Receiver operating characteristic (ROC) curve analyses identified an H-score of 150 or higher (A) or the presence of
at least 70% of cells with a staining intensity of 2þ or higher (B) with use of the SP384 clone as the optimal cutoff value for
identifying ROS1 translocations by fluorescence in situ hybridization (both with 93% sensitivity and 100% specificity).
Regarding the D4D6 clone, the optimal cutoff value was an H-score of at least 100 (C) (with 91% sensitivity and 100%
specificity), followed by the presence of at least 30% of cells with a staining intensity of 2þ or higher (D) (with 86% sensitivity
and 100% specificity). IHC, immunohistochemistry.
December 2019 ROS1 Immunohistochemistry with Clone SP384 2125interest. The test used for comparison of categorical
variables was the Pearson chi-square test (frequency <5
[Fisher exact test]). For comparison of means we used the
Mann-Whitney test. The sensitivity and specificity of both
ROS1 IHC clones versus those of FISH were obtained.
Receiver operating characteristic (ROC) curves were used
to determine the optimal cutoff value that discriminates
between patients with ROS1-rearranged and ROS1-non-
rearranged tumors. We also analyzed the correlation be-
tween the different ROS1 fusion variants and
clinicopathologic features. Survival analysis was per-
formed by using the Kaplan-Meier method with the log-
rank test and Cox regression. All analyses were done
with Stata 15.1 software (StataCorp, College Station, TX)
and were two sided; p values less than 0.05 indicated
statistical significance.Results
ROS1 Rearrangements Assessed by FISH
Of the 55 ROS1-positive lung carcinoma specimens,
four were excluded for lack of sufficient tumor tissue
and eight were excluded because the FISH results were
not evaluable (i.e., no or weak hybridization signals). Of
the 193 ROS1-negative NSCLC specimens, all were
included in the study (see Fig. 1). Among the 43 ROS1
FISH–positive cases analyzed, 27 tumors (62.8%) had a
BA pattern and 16 (37.2%) showed an IGS pattern. The
total number of tumor cells analyzed was 50 in all cases
(97.7%) except in one specimen (2.3%) (a case with
initial borderline results in which 100 nuclei had to be
scored). In ROS1 FISH–negative cases, the mean per-
centage of positive tumor cells was 0.4% (median 0%,
range 0%–10%). In the ROS1 FISH–positive tumors, the
Figure 3. Most of the ROS1-positive tumors showed homogeneous staining with the SP384 clone (A [top inset]), whereas
intratumoral heterogeneity was more frequently observed with the D4D6 antibody (B [upper inset]). Moreover, as shown in
the lower insets, ROS1 expression was more frequent in nonneoplastic type II pneumocytes with use of the SP384 clone (A)
than with use of the D4D6 antibody (B).
2126 Conde et al Journal of Thoracic Oncology Vol. 14 No. 12mean percentage of positive cells was 82.3% (median
86%, range 49%–98%). There were no significant dif-
ferences in the percentages of positive cells between the
two patterns of positivity.Figure 4. Representative images of the different topograph
membranous accentuation staining with the SP384 (A) and D4
granular cytoplasmic staining using the SP384 clone (C) and thROS1 Immunoreactivity by IHC
The IHC results using the previously published
criteria are summarized in Table 1. In addition, the ROC
analyses showed that an H-score of 150 or higheric immunohistochemistry patterns. A tumor with a linear
D6 (B) clones, respectively. Another case with a diffuse and
e D4D6 antibody (D).











Small biopsy 11 (25.6)
Cell block 4 (9.3)



















Lymph nodes 1 (3.8)
Pleural 3 (11.5)
Multiple organs 12 (46.2)





Response rate of crizotinibc
PD 3 (14.3)
Stable disease 1 (4.8)
PR 16 (76.2)
CR 1 (4.8)
aClinical information was available for 41 out of 43 patients.
bPatients with stage IV disease treated with crizotinib (n ¼ 25).
cPatients who were treated with crizotinib and had clinical follow-up in-
formation available (n ¼ 21).
AC, adenocarcinoma; CR, complete response; NOS, not otherwise specified;
PR, partial response; PD, progressive disease; SCC, squamous cell
carcinoma.
December 2019 ROS1 Immunohistochemistry with Clone SP384 2127(criterion 2) or the presence of at least 70% of cells with
at least 2þ staining by the SP384 clone was the optimal
cutoff value for identifying ROS1 translocations by FISH
(both with 93% sensitivity and 100% specificity).
Regarding the D4D6 clone, the optimal cutoff value was
criterion 1 (with 91% sensitivity and 100% specificity),
followed by criterion 4 (Fig. 2). The IHC concordance
between observers was almost perfect (data not shown).
In accordance with the defined optimal criteria, when
the SP384 clone was used, 40 cases (16.9%) were pos-
itive and 196 cases (83.1%) were negative. The mean
H-score of the SP384 ROS1–positive cases was 291
(median 300, range 160–300), and the mean of cells with
staining scored as 2þ or higher was 98.9% (median 100,
range 70–100). Interestingly, in 37 out of 40 SP384
ROS1–positive cases (92.5%), immunoreactivity was
evident as diffuse staining with an intensity of 2þ or
higher. Heterogeneity was present in 7.5% of cases
(Fig. 3A). With the D4D6 clone, we observed 39 positive
cases (16.5%) and 197 negative tumors (83.5%). The
mean H-score of the D4D6 ROS1–positive cases was 243
(median 260, range 100–300), and the mean percentage
of tumor cells with staining graded 2þ or higher was
82.3% (median 90, range 10–100). Of the 39 D4D6
ROS1–positive cases, 22 (56.4%) showed intratumoral
heterogeneity (Fig. 3B). Interestingly, in the positive
cases the difference in intratumoral heterogeneity be-
tween the two clones was statistically significant (p <
0.0001).
Regarding the SP384 ROS1–negative tumors,
immunoreactivity ranged from absent (133 of 196
[67.9%]) to focal and weak (1þ) or moderate (2þ)
staining (63 of 196 [32.1%]), with a mean H-score of
10.6 (median 0, range 0–130) and a mean percentage
of cells with staining graded 2 or higher of 1.9%
(median 0, range 0–40). With the D4D6 clone, 157 out
of 197 ROS1 IHC–negative cases (79.7%) showed
absence of immunoreactivity, whereas the remaining
cases (40 of 197 [20.3%]) exhibited a focal staining
pattern graded 1þ to 2þ. The mean H-score was 3.8
(median 0, range 0–75) and the mean percentage of
cells with staining graded 2þ or higher was 0.6%
(median 0, range 0–20).
We observed the same topographic staining pattern
with both ROS1 IHC antibodies. A granular or diffuse
cytoplasmic staining was present in all cases with immu-
noreactivity (ROS1-positive and ROS1-negative cases),
whereas a linear membranous accentuation was observed
only in ROS1-positive tumors (14 of 40 examined by SP384
IHC [35%] and 14 of 39 examined by D4D6 IHC [35.9%])
(Fig. 4). There was no significant association between the
topographic IHC patterns and the FISH patterns.
Finally, ROS1 expression in nonneoplastic type II
pneumocytes (especially in the periphery of the tumornodule or in a subpleural location) was statistically more
frequent with use of the SP384 clone (104 of 107
[97.2%]) than with use of the D4D6 antibody (63 of 107
[58.9%]) (p < 0.0001) (see Fig. 3).
ROS1 Rearrangements Assessed by NGS
Analysis by NGS was successful in 34 tumors (79%).
Results could not be assessed in nine cases owing to
2128 Conde et al Journal of Thoracic Oncology Vol. 14 No. 12insufficient sequencing coverage: four cases had a very
limited tumor cell content (i.e., 5%–10%), and in five
cases results could not be obtained because of RNA
degradation (for example, one of the biopsy specimens
was a decalcified bone sample). Fourteen cases (41.2%)
had a CD74 molecule gene (CD74)-ROS1 fusion (11 cases
corresponding to CD74 exon 6–ROS1 exon 34 fusion and
three corresponding to CD74 exon 6–ROS1 exon 32
fusion), nine cases (26.5%) showed an ezrin gene (EZR)
exon 10–ROS1 exon 34 fusion, six cases (17.6%) had a
syndecan 4 gene (SDC4) exon 2–ROS1 exon 32 fusion,
four cases (11.8%) presented a solute carrier family 34
member 2 gene (SLC34A2)-ROS1 fusion (three corre-
sponding to SLC34A2 exon 13–ROS1 exon 32 fusion and
one corresponding to SLC34A2 exon 13–ROS1 exon 34
fusion), and finally one sample (2.9%) contained a
tropomyosin 3 gene (TPM3) exon 7–ROS1 exon 35
fusion. Interestingly, among the nine EZR-ROS1–positive
tumors, eight (88.9%) showed membranous accentua-
tion staining with both ROS1 IHC antibodies and six
(66.7%) presented an IGS FISH pattern. Both associa-
tions were statistically significant (p ¼ 0.001 and p ¼
0.017, respectively). CD74-ROS1–positive tumors more
frequently exhibited cytoplasmic staining with both
ROS1 IHC clones (12 versus two [p ¼ 0.009]) and a BA
FISH pattern (10 versus four [p ¼ 0.495]). The results of
all three assays in the FISH-positive cases are detailed in
Supplementary Table 1.Discordances between ROS1 Assays
Of the 43 ROS1 FISH–positive tumors, three showed
absent (0) or focal (1þ) cytoplasmic staining with both
antibodies and were therefore considered ROS1 IHC–
negative with use of all the criteria. Unfortunately, NGS
results were not available for these cases. Clinically, all
three patients were males with a history of smoking.
Interestingly, one patient had metastatic poorly differ-
entiated squamous cell carcinoma diagnosed by a
bronchial biopsy (i.e., p40 positive by IHC), with a pre-
dominantly BA FISH pattern (78% of positive cells); the
patient received crizotinib treatment but had progres-
sive disease. The remaining two patients had adenocar-
cinomas (ACs) that were diagnosed by surgical
specimens (i.e., lung and bone resections) with an IGS
FISH pattern (90% and 52% of positive cells, respec-
tively). Only one of these two patients received crizotinib
and had progressive disease.
Moreover, one ROS1 FISH–positive case (i.e., 98% of
positive cells with an IGS FISH pattern) showed immu-
noreactivity with use of the SP384 clone (with an H-
score of 160 and staining in 70% of tumor cells graded
2þ or higher) and was considered ROS1 IHC–positivewith use of all the criteria. Conversely, immunoreac-
tivity was absent with use of the D4D6 ROS1 antibody.
Clinically, the patient was a 67-year-old smoking male
with a stage IV lung AC that had been diagnosed in a cell
block; he received crizotinib with a partial response. An
NGS result was not available.
In addition, if we consider criteria 2 and 4, two ROS1
FISH–positive cases were clearly positive according to
SP384 antibody staining (i.e., H-scores of 230 and 300
and with 95% and 100% of tumor cells with staining
graded 2þ or higher, respectively), whereas they should
be considered negative according to staining with the
D4D6 clone (i.e., H-scores of 105 and 100 with 20% and
10% of tumor cells with staining graded 2þ or higher,
respectively). NGS confirmed the ROS1 fusions (EZR-
ROS1 and CD74-ROS1 variants, respectively). Clinically,
both patients were nonsmoking males with ACs who
received crizotinib, resulting in objective responses.
All discordant cases were independently reviewed (F.
L-R.), and the results were confirmed. Remarkably, the
results for all ROS1 NGS–positive tumors were in
agreement with those obtained by FISH.Correlation between ROS1 Rearrangements and
Clinicopathologic Data
The clinicopathologic features of the 43 ROS1 FISH–
positive tumors are detailed in Table 2. Briefly, 31
cases (72.1%) were diagnosed as primary lung cancer
(cancer originating in the lung), whereas 12 (27.9%)
were metastases from different sites. Thirty-nine tumors
(90.7%) were ACs, one (2.3%) was a squamous cell
carcinoma, and the remaining three (7%) were NSCLCs
not otherwise specified. Of the 39 ACs, 20 (51.3%) were
observed to have a predominant acinar pattern, 14
(35.9%) presented a solid architecture, two (5.1%) had a
predominant lepidic pattern, one (2.6%) showed a
papillary growth, and one (2.6%) had a predominant
micropapillary pattern. Mucinous and/or signet ring
cells were observed in six out of 39 ACs (15.4%).
Interestingly, psammomatous calcifications and pleo-
morphic features were frequently observed (in 18.6%
and 30.2% of tumors, respectively).
Clinical data were available for 41 patients (see Fig. 1
and Table 2). Briefly, the overall response rate was 81%
and the disease control rate was 85.7%. At the time of
report, the median progression-free survival (PFS) and
overall survival times were 10.8 and 16.6 months,
respectively. There were no relevant associations be-
tween ROS1 fusion variants and clinicopathologic char-
acteristics, except for a nonsignificant trend toward
better PFS in patients with the EZR-ROS1 variant
(p ¼ 0.199).
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This multicenter study provided real-world data on
ROS1 rearrangements in patients with NSCLC. To the
best of our knowledge, this series represents one of the
largest ROS1-positive lung cancer cohorts ever assem-
bled. Considering that patients with ROS1 rearrangement
represent only 1% to 2% of the overall population with
NSCLC, few reports contain more than 50 patients.18-23
Moreover, a careful review of published studies identi-
fied only two larger series in which positive tumors had
been investigated with more than two methodolo-
gies.19,22 One potential caveat of our work is that it is a
retrospective series and therefore conclusions regarding
ROS1 inhibition are limited. To partially overcome this
shortcoming, it is relevant to emphasize that all samples
were initially tested with intention to treat, so our
findings represent the clinical reality. In fact, the clinical
results are in complete agreement with those of other
series.4,24 Moreover, we used commercially available
tools, so our findings could be replicated elsewhere.
Although the recently updated CAP/IASLC/AMP mo-
lecular testing guidelines allow the use of ROS1 IHC for
screening purposes, there has been only one antibody
available to date (D4D6).9-11 The sensitivity for this
clone was controversial, probably reflecting the different
interpretation criteria and the small numbers that were
tested in most studies (reviewed in9,10,25-28). The recent
release of a new clone (SP384), with only one published
report available to date, provides an in vitro diagnostic
alternative.23
Several conclusions can be drawn from our study.
SP384 is more sensitive than D4D6 when compared with
FISH, regardless of the criterion used. There are two
differential features of SP384 that can be extremely
useful to reduce the risk of a false-negative result. First,
there is the extremely frequent homogeneous staining
(>92%) for ROS1. Considering the small size and limited
number of fragments of most lung biopsy specimens, the
sensitivity of some predictive IHC tests on small biopsy
specimens has been challenged owing to heterogeneous
expression.29 Therefore, it is tempting to speculate that a
less heterogeneous pattern of staining is an advantage in
this setting. Second, there is the constant staining of
nonneoplastic type II pneumocytes (>95%), which can
be used as an in situ performance control. External
positive controls should not be used to rule out a false-
negative result caused by suboptimal preanalytical pa-
rameters.12 No matter how much one monitors this
phase of the procedure, samples will occasionally fail.
Along these lines, all but one of the IHC false-negative
samples in our series were precisely specimens that
are usually more prone to preanalytical artifacts: two
surgical resections, a decalcified bone specimen, and acell block (the only true discordant positive sample be-
tween both clones). Accordingly, pathologists should try
to select blocks for ROS1 IHC testing that contain normal
lung, and extreme caution must be taken afterward so as
not to overinterpret the immunoreactivity in such
normal or hyperplastic pneumocytes.11,15 Along these
lines, positivity with D4D6 has been described in ROS1-
nonrearranged tumors having lepidic patterns of growth
or containing EGFR mutations (see the next para-
graph).14,30 This potentially confounding situation could
be used to our advantage when searching for external
positive controls.
Although our findings in the ROS1-nonrearranged
cohort should be interpreted with extreme caution to
avoid sample size bias,31,32 we truly believe that the
results might represent the clinical reality (i.e., these
were not referral cases, and we chose not to use tissue
microarrays). The specificity of the two clones could
very well be 100% if very stringent interpretation
criteria were used. The best option would be an H-score
of at least 100 for D4D6, but the higher sensitivity of
SP384 comes at a cost and higher cutoffs are needed to
avoid what could be considered an excessive number of
orthogonal tests (98% versus 100% specificity). How-
ever, a broadly held consensus on the interpretation
criteria required for a positive IHC score has yet to
emerge.10,11 There are several lines of evidence that are
worth considering when addressing this matter. Un-
questionable ROS1 IHC expression (i.e., even strong but
focal) with D4D6 has been described in ROS1-non-
rearranged cases containing other druggable alterations
(mainly EGFR mutations, but also KRAS mutations, BRAF
mutations, ALK receptor tyrosine kinase gene [ALK] fu-
sions, and erb-b2 receptor tyrosine kinase 2 gene [HER2]
abnormalities), and we have had anecdotal analogous
experience with SP384 (E. Conde, unpublished obser-
vation, 2019).14-16,25,30,33,34 Therefore, it is not surpris-
ing that the analytical comparison data of SP384 versus
FISH released by the manufacturer achieves the best
balance between negative and positive agreement at the
50% cutoff, a result similar to that of our ROC curve
analyses.35 Nonetheless, the interreader precision of
SP384 has been reported as high even with use of a
lower cutoff (30%), so higher cutoffs should not be an
interpretation challenge in the real clinical world.17
Accordingly, a recent study has also reported a high
interpathologist agreement when interpreting both
clones.23 In the light of the aforementioned, extreme
caution is advised in settings with a very high incidence
of patients with EGFR mutation (or other druggable non-
ROS1 genomic drivers, for that matter) so as not to
render useless the screening value of ROS1 IHC (see later
in this discussion).
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the criterion standard test for detection of ROS1 rear-
rangements, the ROS1 FISH is especially difficult to
interpret and may be prone to both false negatives and
false positives.9,11,19,36-40 To increase the robustness of
the results, we decided to repeat all FISH tests in house
and score them with an outstanding automated FISH
scanning system using a high threshold for positivity.
The mean and median numbers of positive cells in pos-
itive tumors were very high (>80%, which is well above
the threshold) and obviously contributed to the excellent
correlation with FISH, but it must be emphasized that
some rare fusion partners ([GOPC], which is also known
as FIG, occurs in 3% of ROS1 patients and is not repre-
sented in the present study) are a well-known source of
false-negative FISH results.14,39,41,42 Conversely, we and
others have reported that bona fide ROS1-nonrearranged
tumors can contain a number of positive nuclei (10%–
12%), which is close to the 15% cutoff used in many
studies.9,15,16 At least some published reports with a
high prevalence of concomitant oncogene mutations may
reflect problems with the FISH interpretation.43,44 The
use of imaging systems and/or a higher threshold for
positivity are strategies that should ensure
specificity.9,11,15,16
In the last phase of the study, we performed an RNA-
based NGS assay in FISH-positive cases to understand the
molecular epidemiology of the different rearrangements
and try to correlate them with the clinical and patho-
logical features. It must be emphasized that this was not a
formal comparison study between different methodolo-
gies. Overall, the variety and prevalence of ROS1 partners
identified were similar to those described.24,37,45 The
percentage of cases in which the suboptimal RNA quality
and/or quantity resulted in low sequencing coverage
highlights the need for an evidence-based algorithmic
approach.39,46,47 The fusion partner can influence both
the IHC staining and the FISH pattern, with the EZR
variant usually being associated with a membranous
accentuation and isolated 30 signals, respec-
tively.13,14,25,45 This latter association could explain some
of the cases with false-negative FISH results that were
found to contain the EZR-ROS1 transcript, as this atypical
pattern is in fact the most difficult to score because the
isolated 30signals can sometimes be absent or barely
visible.9,13,40 Finally, our nonsignificant trend of better
PFS for patients with the EZR-ROS1 fusion might be in
alignment with the results of series in which almost every
patient with an IGS achieved a complete response and
with the recently published differential efficacy of crizo-
tinib in the non–CD74-ROS1 group.24,48 Unfortunately,
this is still a controversial topic that would need larger
multicenter series with longer follow-up and standard-
ized NGS to draw definitive conclusions.22,37A review of published studies in the light of our
findings suggests that there are two scenarios that can
have important clinical consequences when ROS1 IHC is
to be used as the primary screening method for ROS1
therapy: (1) a ROS1 FISH–false-positive result in a pa-
tient with another druggable alteration that is causing
the ROS1 IHC positivity (awareness of the FISH poten-
tial pitfalls is essential [i.e., percentage of positive
nuclei around the cutoff, 30 isolated pattern], and if the
result is inconsistent, it is sensible to use a third
methodology [i.e., NGS], which will potentially discover
the reason for the IHC positivity) and (2) a ROS1 NGS–
negative or failed report in a ROS1-rearranged sample
that exhibited intense and homogeneous IHC stain-
ing.38,44 The choice of RNA-based NGS can reduce the
risk of false negatives, and using another sample or a
third technology (i.e., FISH) when the initial NGS
approach fails is mandatory to confirm those positive
IHC results.39,47
In conclusion, the new SP384 clone showed high
sensitivity without compromising specificity, so it is
another excellent analytical option for the proposed
CAP/IASLC/AMP molecular testing algorithm. Consider-
ation of the clinical problem of NSCLC highlights the
need to be aware of how the methods that we use
perform in the real-world setting.46Acknowledgments
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